MESO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland...

Stats
Dzisiejszy wolumen	282 718
Średni wolumen	2.28M
Kapitalizacja rynkowa	855.93M
EPS	$0 ( 2024-03-25 )
Następna data zysków	( $-0.320 ) 2024-05-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.52
ATR14	$0.0190 (0.25%)

Wolumen Korelacja

Długi: 0.16 (neutral)

Krótki: 0.76 (moderate)

Signal:(56.007) Neutral

Mesoblast Limited Korelacja

10 Najbardziej pozytywne korelacje
PFSW	0.949
LABP	0.944
DSGN	0.941
NN	0.94
CTIC	0.936
PRVB	0.93
CDXC	0.927
PESI	0.927
IDN	0.92
SCTL	0.919

10 Najbardziej negatywne korelacje
LIAN	-0.939
SBNYP	-0.928
LUCD	-0.923
LUNA	-0.922
NOVN	-0.912
NLSP	-0.909
AEY	-0.908
PRFT	-0.908
AZ	-0.907
EZGO	-0.905

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mesoblast Limited Korelacja - Waluta/Towar

-0.64
( weak negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.60
( weak negative )

0.50
( neutral )

0.66
( moderate )

Mesoblast Limited Finanse

Annual	2023
Przychody:	$7.50M
Zysk brutto:	$-20.23M (-269.72 %)
EPS:	$-1.050

FY	2023
Przychody:	$7.50M
Zysk brutto:	$-20.23M (-269.72 %)
EPS:	$-1.050

FY	2022
Przychody:	$10.21M
Zysk brutto:	$-20.55M (-201.21 %)
EPS:	$-1.330

FY	2021
Przychody:	$7.46M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.817

Financial Reports:

No articles found.

Mesoblast Limited

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.